Marino Stram & Associates’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $766K | Sell |
31,798
-1,009
| -3% | -$26.4K | 0.12% | 100 |
|
|
2026
Q1 | $921K | Buy |
32,807
+24
| +0.1% | +$639 | 0.17% | 82 |
|
|
2025
Q4 | $816K | Sell |
32,783
-5,032
| -13% | -$127K | 0.15% | 95 |
|
|
2025
Q3 | $964K | Sell |
37,815
-180
| -0.5% | -$4.44K | 0.17% | 91 |
|
|
2025
Q2 | $921K | Sell |
37,995
-6,590
| -15% | -$154K | 0.19% | 86 |
|
|
2025
Q1 | $1.13M | Sell |
44,585
-2,588
| -5% | -$67.7K | 0.25% | 66 |
|
|
2024
Q4 | $1.25M | Sell |
47,173
-3,082
| -6% | -$83.6K | 0.28% | 57 |
|
|
2024
Q3 | $1.45M | Buy |
50,255
+1,741
| +4% | +$50.8K | 0.32% | 51 |
|
|
2024
Q2 | $1.36M | Sell |
48,514
-2,384
| -5% | -$65.6K | 0.33% | 49 |
|
|
2024
Q1 | $1.41M | Sell |
50,898
-5,285
| -9% | -$147K | 0.33% | 47 |
|
|
2023
Q4 | $1.62M | Sell |
56,183
-8,554
| -13% | -$259K | 0.42% | 43 |
|
|
2023
Q3 | $2.15M | Sell |
64,737
-2,866
| -4% | -$101K | 0.63% | 30 |
|
|
2023
Q2 | $2.49M | Buy |
67,603
+1,664
| +3% | +$64.8K | 0.7% | 23 |
|
|
2023
Q1 | $2.69M | Buy |
65,939
+949
| +1% | +$41K | 0.81% | 20 |
|
|
2022
Q4 | $3.33M | Buy |
64,990
+376
| +0.6% | +$18K | 1.05% | 14 |
|
|
2022
Q3 | $2.83M | Buy |
64,614
+851
| +1% | +$41.4K | 1.02% | 16 |
|
|
2022
Q2 | $3.34M | Buy |
63,763
+443
| +0.7% | +$22.6K | 1.16% | 13 |
|
|
2022
Q1 | $3.28M | Buy |
63,320
+602
| +1% | +$31.2K | 1.03% | 15 |
|
|
2021
Q4 | $3.7M | Buy |
62,718
+1,966
| +3% | +$97.4K | 1.14% | 15 |
|
|
2021
Q3 | $2.61M | Sell |
60,752
-25,938
| -30% | -$1.15M | 0.9% | 19 |
|
|
2021
Q2 | $3.4M | Buy |
86,690
+31,446
| +57% | +$1.22M | 0.89% | 31 |
|
|
2021
Q1 | $2M | Buy |
55,244
+4,962
| +10% | +$176K | 0.78% | 26 |
|
|
2020
Q4 | $1.85M | Buy |
50,282
+350
| +0.7% | +$12.8K | 0.82% | 24 |
|
|
2020
Q3 | $1.74M | Buy |
49,932
+1,768
| +4% | +$62K | 0.93% | 25 |
|
|
2020
Q2 | $1.49M | Buy |
48,164
+7,971
| +20% | +$271K | 0.89% | 24 |
|
|
2020
Q1 | $1.25M | Buy |
40,193
+5,751
| +17% | +$196K | 0.96% | 21 |
|
|
2019
Q4 | $1.28M | Sell |
34,442
-1,742
| -5% | -$62K | 0.84% | 21 |
|
|
2019
Q3 | $1.23M | Buy |
36,184
+129
| +0.4% | +$4.69K | 0.87% | 21 |
|
|
2019
Q2 | $1.48M | Buy |
36,055
+3,316
| +10% | +$132K | 1.09% | 19 |
|
|
2019
Q1 | $1.32M | Buy |
32,739
+2,043
| +7% | +$81.8K | 0.95% | 19 |
|
|
2018
Q4 | $1.3M | Sell |
30,696
-666
| -2% | -$27.6K | 1.14% | 19 |
|
|
2018
Q3 | $1.31M | Sell |
31,362
-2,988
| -9% | -$115K | 1.05% | 19 |
|
|
2018
Q2 | $1.18M | Buy |
34,350
+343
| +1% | +$11.7K | 1.05% | 19 |
|
|
2018
Q1 | $1.15M | Buy |
34,007
+99
| +0.3% | +$3.4K | 1.06% | 21 |
|
|
2017
Q4 | $1.17M | Buy |
+33,908
| New | +$1.16M | 1.08% | 19 |
|
Other funds holding PFE
AIM
SLAM
CWP
Marino Stram & Associates's PFE Position: Q2 2026 in Review
Marino Stram & Associates reduced its Pfizer (PFE) stake by 3.1% in Q2 2026, selling an estimated $26.4K and leaving 31,798 shares worth $766K. The position accounts for 0.12% of the portfolio, ranked #100.
Marino Stram & Associates first reported a position in PFE in Q4 2017 and has held it in 35 quarters since. The position peaked at $3.7M in Q4 2021. 1,336 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Marino Stram & Associates held 31,798 shares of Pfizer worth $766K as of Q2 2026.
- Marino Stram & Associates sold 1,009 Pfizer shares in Q2 2026, an estimated $26.4K.
- Pfizer made up 0.12% of Marino Stram & Associates's portfolio in Q2 2026, its #100 holding.
- Marino Stram & Associates first reported a position in Pfizer in Q4 2017 and has held it in 35 quarters since.
- Marino Stram & Associates's Pfizer position peaked at $3.7M in Q4 2021.
- 1,336 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Marino Stram & Associates's 13F filing for Q2 2026, filed 24 Jul 2026.